
                      polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial by unknown
Ulivi et al. J Transl Med  (2015) 13:258 
DOI 10.1186/s12967-015-0619-5
RESEARCH
eNOS polymorphisms as predictors 
of efficacy of bevacizumab-based 
chemotherapy in metastatic colorectal cancer: 
data from a randomized clinical trial
Paola Ulivi1*†, Emanuela Scarpi2†, Alessandro Passardi3, Giorgia Marisi1, Daniele Calistri1, Wainer Zoli1, 
Marzia Del Re4, Giovanni Luca Frassineti3, Davide Tassinari5, Stefano Tamberi6, Bernadette Vertogen2 
and Dino Amadori3
Abstract 
Background: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of meta-
static colorectal cancer (mCRC). However, molecular predictors of bevacizumab efficacy have not yet been identified. 
We analyzed vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) polymorphisms in 
relation to response to bevacizumab.
Methods: Two hundred and thirty-seven patients with mCRC enrolled onto the phase III prospective multicentre 
randomized “Italian Trial in Advanced Colorectal Cancer (ITACa)” trial were evaluated. One hundred fourteen patients 
received chemotherapy plus bevacizumab (CT + B) and 123 received chemotherapy (CT) alone. Five single nucleo-
tide polymorphisms (SNPs) (−2578, −1498, −1154, −634 and +936) for VEGF and 2 SNPs (−786, +894) and one vari-
able number tandem repeat in intron 4 for eNOS were analyzed for each patient. The polymorphisms were assessed in 
relation to progression-free survival (PFS), objective response rate (ORR) and overall survival (OS).
Results: VEGF 936C/T, eNOS +894 G/T and VNTR were significantly correlated with outcome in CT + B patients, but 
not in CT-only patients. In particular, patients with a specific haplotype combination of the 2 eNOS polymorphisms 
(defined eNOS Haplo1/Haplo1 and eNOS Haplo 2/Haplo2) showed significantly longer PFS (15.0 vs 9.1 months, 
P = 0.001) and OS (34.5 vs 20.5 months P = 0.002), and a higher ORR (71 vs 45.9%, P = 0.013) than those with the 
other genotypes, respectively.
Conclusions: Specific eNOS polymorphisms may be capable of identifying a subset of mCRC patients who are more 
responsive to bevacizumab-based chemotherapy. If confirmed, these results would permit individually tailored treat-
ment with bevacizumab.
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Background
The therapeutic approach to metastatic colorectal can-
cer (mCRC) has changed in recent years, mainly thanks 
to the introduction of biologic drugs such as cetuximab, 
a monoclonal antibody (MoAb) directed against the epi-
dermal growth factor receptor (EGFR), or bevacizumab, 
a MoAb that blocks the vascular endothelial growth fac-
tor (VEGF) [1]. As RAS-mutated patients show no ben-
efit from anti-EGFR therapy, RAS mutations are used as 
a marker to select candidates for cetuximab treatment 
[2, 3]. However, they are not predictive of the efficacy of 
bevacizumab [4, 5], for which there are still no known 
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biomarkers that are capable of distinguishing between 
responsive and non responsive patients. The correct 
selection of patients to be treated with bevacizumab-
based chemotherapy could allow for the drug only to be 
given to those patients who will really benefit from it and 
for a reduction in the number of adverse effects.
Some studies have reported that specific VEGF single 
nucleotide polymorphisms (SNPs) would seem to affect 
gene transcription, with a consequent variation in VEGF 
expression [6, 7]. Other studies have evaluated the role 
of VEGF SNPs in relation to response to bevacizumab 
[8–12], the contradictory results reported possibly due 
to different study designs. In a retrospective study by 
Loupakis and colleagues, VEGF −1498 C/T variants 
proved capable of predicting response to bevacizumab 
plus FOLFIRI [11]. Similarly, in a more recent study [10], 
the same variants together with VEGF −2578 C/A were 
shown to predict response to bevacizumab treatment. 
A prospective study by Koutras and colleagues reported 
that only the VEGF −1154 G/A variants were associ-
ated with response and overall survival (OS) in patients 
treated with bevacizumab plus FOLFIRI or XELIRI [9]. 
The same VEGF SNPs were associated with progression-
free survival (PFS) in another study [8] in which VEGF 
−634 G/C was associated with response. These SNPs 
have also been associated with cardiovascular adverse 
effects induced by bevacizumab, in particular, hyperten-
sion [10], and a correlation has been reported between 
response and bevacizumab-induced hypertension [13]. 
Recently, another study found that VEGF and endothelial 
nitric oxide synthase (eNOS) polymorphisms were asso-
ciated with sunitinib-induced hypertension in patients 
with metastatic renal cancer, with grade three hyperten-
sion identified as an independent predictor of OS [14].
In the present study, we analyzed VEGF and eNOS 
polymorphisms in relation to clinical outcome (PFS, 
overall response rate [ORR] and OS) in mCRC patients 
undergoing bevacizumab-based chemotherapy in the 
phase III prospective multicentre randomized “Ital-
ian Trial in Advanced Colorectal Cancer (ITACa)” 




The study was approved by the Local Ethics Com-
mittee (Comitato Etico Area Vasta Romagna e IRST) 
and informed consent was obtained from all patients 
before blood samples were obtained for genotype test-
ing. Participation in the ITACa biological study was 
not mandatory for those taking part in the clinical 
trial. Of the 376 patients with mCRC enrolled onto 
the ITACa trial, 237 had sufficient biological material 
archived to be considered for this planned secondary 
analysis.
Inclusion criteria, patient characteristics, randomiza-
tion strategy and the clinical results of the ITACa study 
are reported elsewhere [15]. Patients were randomized to 
receive first-line chemotherapy (CT) (FOLFOX4 or FOL-
FIRI) only or CT plus bevacizumab (B). FOLFOX4 con-
sisted of oxaliplatin 85  mg/m2 as a 2-h infusion on day 
one and leucovorin 100 mg/m2 as a 2-h infusion followed 
by bolus 5-FU 400  mg/m2 and a 22-h infusion of 5-FU 
600  mg/m2 on days 1–2 every 2  weeks. FOLFIRI con-
sisted of the same 5-FU +leucovorin regimen with the 
addition of irinotecan 180  mg/m2 as a 90-min infusion 
on day one. B was administered as a 30- to 90-min intra-
venous infusion at a dose of 5  mg/kg on day 1 of each 
2-week cycle. Treatment was to be continued until pro-
gressive disease (PD), withdrawal of consent or unaccep-
table toxicity, whichever came first. Tumor assessment 
tests were performed within 28 days of starting the study 
treatment and repeated every 8 weeks during treatment 
until PD.
The clinical characteristics of patients are represented 
in Table 1. One hundred and fourteen patients received 
CT  +  B and 123 patients received CT only (control 
group). We considered KRAS status as an independent 
variable because it was a stratification factor in the clini-
cal study. Furthermore, to our knowledge, there are no 
significant data in the literature that attest to the fact that 
KRAS plays a role in response to bevacizumab.
All patients were evaluated for response [according to 
Response Evaluation Criteria in Solid Tumors (RECIST) 
guidelines], PFS and OS. In particular, response was clas-
sified as complete response (CR), partial response (PR), 
stable disease (SD) or PD, and patients with CR or PR 
were defined as responsive.
Genomic DNA extraction
Peripheral blood samples were available for polymor-
phism analysis in 153 patients, whereas only paraffin-
embedded tumor samples were available for 84 patients.
Genomic DNA was extracted from whole blood using 
QIAamp DNA Minikit (Qiagen SPA, Milan, Italy) fol-
lowing the manufacturer’s protocol. DNA was extracted 
from formalin-fixed paraffin- embedded (FFPE) tumor 
tissue starting from 5-μM FFPE tissue sections. Tissue 
was lysed in 50 mM of KCl, 10 mM of Tris–HCl pH 8.0, 
2.5  mM of MgCl2 and Tween-20 0.45%, supplemented 
with Proteinase K at a concentration of 1.25  mg/ml, 
overnight at 56°C. Proteinase K was inactivated at 95°C 
for 10  min, after which samples were centrifuged twice 
to eliminate debris. Supernatant was assessed for DNA 
Page 3 of 10Ulivi et al. J Transl Med  (2015) 13:258 
quality and quantity by Nanodrop (Celbio Spa, Milan, 
Italy) and then underwent molecular analysis.
Genotyping analyses
Genotyping was performed for five VEGF SNPs (VEGF 
−2578C>A, −1498C>T, −1154G>A, −634C>G, 
+936C>T) and for two SNPs (eNOS −786T>C, 
+894G>T) and one variable number tandem repeat 
(VNTR) of 27 nucleotides for eNOS. The localizations 
and refSNP (rs) numbers of the different polymorphisms 
are shown in Fig.  1. All but eNOS −786 were analyzed 
by direct sequencing. The primer sequences and PCR 
conditions are reported in an Additional file 1. PCRs were 
performed starting from 50 ng of genomic DNA. eNOS-
786 was analyzed by Real-Time PCR using a TaqMan 
SNP Genotyping assay (Assay ID C_15903863_10, 
Applied Biosystems, Foster City, CA, USA) and starting 
from 10 ng of DNA.
Statistical analysis
All polymorphisms were examined for deviation from 
Hardy–Weinberg equilibrium (HWE) by comparing 
actual allelic distributions with those expected from 
HWE using a χ2 test. Lewontin’s standardised disequilib-
rium coefficient (D′) among investigated polymorphisms 
was assessed using the HaploView programme [16]. The 
software provides the D′ coefficient as a measure of the 
non-random association of alleles at different loci. D′ 
coefficient is equal to one only if two SNPs have not been 
separated by recombination (or recurrent mutation) dur-
ing the history of the sample [complete degree of linkage 
disequilibrium (LD)]. The same software was used to per-
form haplotype analysis.
The primary aim of the ITACa study was PFS. Second-
ary efficacy endpoints were ORR and OS. PFS was calcu-
lated from the date of randomization to the date of the 
first observation of disease progression or last follow-up 
or death in the absence of progressive disease. OS was 
calculated from the date of randomization to the date 
of death from any cause, or last follow-up. PFS, OS and 
their 95% confidence intervals (95% CI) were estimated 
using the Kaplan–Meier method.
SNPs and haplotypes and clinical outcomes were ana-
lyzed separately in each treatment group (CT  +  B and 
CT). Adjusted HRs by baseline characteristics (gender, 
age, performance status, KRAS status, tumor localization 
(rectum/colon) and chemotherapy regimen (FOLFOX4/
FOLFIRI) were calculated using the Cox proportional-
hazard model. Two-sided 95% CIs for each HR were 
provided. Covariate selection was based on a list of prob-
able prognostic factors from the ITACa study [15]. Asso-
ciations between polymorphisms or haplotypes and ORR 
(CR + PR) were analyzed by logistic regression models. 
Odds ratios (OR) and 95% CI were adjusted for gender, 
age, performance status, KRAS status, tumor localization 
(rectum/colon) and chemotherapy regimen (FOLFOX4/
FOLFIRI).
All P values were based on two-sided testing; to miti-
gate the issue of multiple testing, a false discovery rate 
(FDR) of less than 10% was used to determine polymor-
phisms or haplotypes associated with PFS, OS and ORR. 
FDR was controlled using the Benjamini-Hochberg step-
up procedure [17]. The effect of the interaction between 
SNPs or haplotypes and treatment on PFS was evaluated 
Table 1 Patient Characteristics
a Mandatory as consequence of amendment n.1 of 3 May 2009.




Median age, years (range) 66 (34–83) 67 (37–82)
Gender
 Male 70 (61.4) 74 (60.2)
 Female 44 (38.6) 49 (39.8)
Performance status (ECOG)
 0 97 (85.1) 102 (82.9)
 1 17 (14.9) 21 (17.1)
Tumor localization
 Rectum 31 (27.2) 34 (27.6)
 Colon 83 (72.8) 89 (72.4)
Histology
 Adenocarcinoma 104 (91.2) 119 (96.8)
 Mucinous adenocarcinoma 10 (8.8) 4 (3.2)
Grade
 1 0 0
 2 56 (64.4) 67 (65.1)
 3 31 (35.6) 36 (34.9)
 Unknown 27 20
Stage at diagnosis
 I–III 29 (26.4) 31 (27.2)
 IV 81 (73.4) 83 (72.8)
 Unknown 4 9
Chemotherapy regimen planned
 FOLFOX4 69 (60.5) 73 (59.4)
 FOLFIRI 45 (39.5) 50 (40.6)
KRAS statusa
 Wild type 67 (59.8) 69 (58.5)
 Mutated 45 (40.2) 49 (41.5)
 Unknown 2 5
Prior cancer therapy
 Surgery 88 (77.2) 91 (74.0)
 Radiotherapy 11 (9.6) 11 (8.9)
 Adjuvant chemotherapy 18 (15.8) 17 (13.8)
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using Cox regression models of the entire population 
(CT + B and CT arms) that included SNPs or haplotypes, 
treatment and treatment-by-SNPs or -haplotypes. Statis-
tical analyses were performed using SAS Statistical soft-
ware version 9.3 (SAS Inc., Cary, NC, USA).
Results
We previously demonstrated that VEGF and eNOS poly-
morphism analysis showed concordant results regard-
less of starting material used (FFPE or blood sample) in 
all but the VEGF −1154G>A SNP [18]. On the basis of 
this observation, VEGF −1154G>A was only analyzed in 
patients for whom peripheral blood samples were avail-
able (153 patients).
The observed allele distributions of VEGF −2578, 
−1498, −1154, −634, +936 polymorphisms and eNOS 
+894, −786, VNTR 4a/b are shown in an Additional 
file  2; all were in HWE (P  =  0.95; P  =  0.95, P  =  0.12, 
P  =  0.30, P  =  0.91, P  =  0.50, P  =  0.85, P  =  0.26 
respectively).
In accordance with the primary endpoint of the ITACA 
trial, we analyzed the association between the differ-
ent polymorphisms and PFS in the CT + B and CT only 
groups. At a median follow-up of 36  months (range 
1–65), there had been 103 (90.4%) and 115 (93.5%) pro-
gressions and 82 (71.9%) and 91 (74.0) deaths in the 
CT + B and CT groups, respectively.
In the CT +  B group, only the VEGF +936 T/C pol-
ymorphism was significantly associated with PFS; in 
particular, the VEGF +936 TT genotype was associ-
ated with a shorter median PFS compared with other 
genotypes (7.8 months, 95% CI 1.7–9.1 vs. 10.2 months, 
95% CI 9.0–12.4, P  =  0.036) (Table  2). No statistically 
significant differences were observed in the CT-only 
group (Table  2). Of note, the p value did not reach the 
P value threshold adjusted for multiple testing, possi-
bly due to the small number of patients (3) with a VEGF 
+936 TT genotype. eNOS +894 G/T was also associated 
with PFS, and patients with eNOS +894 G/T showed a 
shorter PFS (8.9  months, range 6.8–10.2  months) than 
those with eNOS +894 GG/TT (11.9  months, range 
9.6–14.1 months, P = 0.013) in the CT + B arm (Table 2; 
Additional file  3: Figure S1, panel A). This polymor-
phism was statistically significant after FDR correction. 
Conversely, no differences were observed in the control 
group (Table  2, Additional file  3: Figure S1, panel B). 
Moreover, eNOS VNTR 4a/b was associated with PFS in 
the CT + B arm. Patients homozygous for the five rep-
etitions (VNTR 4bb) showed a longer PFS (10.9 months, 
range 9.1–12.9 months) than those with other genotypes 
(9.1 months, range 6.2–11.3 months, P = 0.034) (Table 2; 
Additional file 3: Figure S1, panel C). No statistically sig-
nificant differences were observed in the control group 
(Table 2, Additional file 3: Figure S1, panel D).
Fig. 1 VEGF and eNOS polymorphisms (with rs reference numbers) analyzed in the study.
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Formal tests of interaction between SNPs and treat-
ment were not significant.
Polymorphisms were also investigated in relation to 
ORR and OS. For VEGF SNPs, only VEGF −634 G/C was 
associated with ORR, a lower rate seen in heterozygous 
patients compared to the other genotypes (P  =  0.017) 
(see Additional file 4). With regard to eNOS, eNOS +894 
G/T was significantly associated with ORR, heterozygous 
patients showing a lower ORR (42.5%) than the other 
genotypes (63.1%) (P = 0.030) (see Additional file 4). No 
polymorphism reached the P value threshold adjusted 
for multiple testing. No significant associations were 
observed between VEGF and eNOS polymorphisms and 
ORR in the control group (data not shown).
With regard to OS, patients bearing the VEGF −634 
GC genotype showed a shorter OS (19.3  months, 95% 
CI 13.1–22.0) than those with the VEGF −634 GG/CC 
genotype (29.1 months, 95% CI 20.9–33.5), although the 
difference was not statistically significant (P  =  0.064) 
(Table  3). No statistically significant differences were 
observed in the control group (Table  3). Moreover, 
patients bearing the VEGF +936 TT genotype showed a 
significantly shorter median OS than VEGF +936 TC/CC 
patients (8.6  months, 95% CI 7.9–13.9 vs 22.7  months, 
95% CI 20.5–27.5, respectively, P  =  0.007; these data 
remained statistically significant after FDR correction) 
(Table 3). With regard to eNOS polymorphisms and OS, 
eNOS +894 G/T was again found to be associated with 
outcome. In particular, patients bearing the eNOS +894 
GT genotype showed a shorter OS (20.1  months, 95% 
CI 12.0–23.2) compared to eNOS +894 GG/TT patients 
(26.1  months, 95% CI 21.0–33.5, P  =  0.014) (Table  3). 
These data remained statistically significant after FDR 
correction. No statistically significant differences were 
observed in the control group (Table  3). Finally, eNOS 
VNTR 4a/b was also associated with OS, and patients 
with a VNTR 4bb genotype showed a longer OS 
(24.8 months, 95% CI 20.1–34.5) compared to those with 
the eNOS VNTR 4ab/aa genotype (20.6 months, 95% CI 
13.7–24.7, P  =  0.015; not significant after FDR correc-
tion) (Table 3). No differences were observed in the con-
trol group (Table 3).
Table 2 Association between VEGF and eNOS polymorphisms and progression–free survival (PFS)
*Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).
Polymorphisms CT + B CT
Median PFS (95% CI) HR (95% CI) P* Median PFS (95% CI) HR (95% CI) P*
VEGF −2578
 AA 9.3 (3.1–12.5) 1.18 (0.72–1.93) 9.1 (7.8–11.4) 1.27 (0.81–1.99)
 CC/CA 10.4 (8.9–12.4) 1.00 0.515 9.0 (7.8–10.3) 1.00 0.304
VEGF −1498
 CC 9.1 (6.4–12.5) 1.30 (0.81–2.11) 9.1 (7.8–11.4) 1.21 (0.77–1.90)
 TT/CT 10.7 (9.1–12.4) 1.00 0.277 9.0 (7.8–10.3) 1.00 0.406
VEGF −1154
 AA 11.5 (2.3–18.5) 1.09 (0.54–2.21) 9.1 (3.1–12.2) 1.74 (0.89–3.38)
 GA/GG 10.3 (8.3–12.9) 1.00 0.808 9.6 (8.9–11.3) 1.00 0.105
VEGF −634
 GC 9.1 (7.5–11.3) 1.21 (0.81–1.82) 9.0 (7.0–10.3) 1.14 (0.77–1.68)
 GG/CC 11.7 (9.1–12.9) 1.00 0.356 9.1 (8.0–11.3) 1.00 0.513
VEGF +936
 TT 7.8 (1.7–9.1) 3.63 (1.09–12.14) 28.0 (–) 0.34 (0.04–2.76)
 CT/CC 10.2 (9.0–12.4) 1.00 0.036 9.1 (8.3–10.2) 1.00 0.311
eNOS +894
 GT 8.9 (6.8–10.2) 1.70 (1.12–2.60) 9.0 (7.4–9.6) 1.06 (0.73–1.54)
 GG/TT 11.9 (9.6–14.1) 1.00 0.013 10.0 (8.3–11.4) 1.00 0.773
eNOS VNTR
 4bb 10.9 (9.1–12.9) 0.63 (0.41–0.96) 9.1 (8.3–10.3) 1.09 (0.69–1.74)
 4ab/4aa 9.1 (6.2–11.3) 1.00 0.034 8.9 (6.1–11.6) 1.00 0.708
eNOS −786
 CC 12.7 (4.7–14.3) 0.90 (0.52–1.56) 8.9 (4.2–11.5) 1.17 (0.68–2.03)
 CT/TT 9.6 (8.5–11.3) 1.00 0.709 9.1 (8.6–10.3) 1.00 0.572
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Haplotype analysis
Haplotype analysis was performed to evaluate the 
combined effect of SNPs in the promoter, 5′UTR and 
3′UTR of the VEGF gene on treatment response. Anal-
ysis showed a single block of high linkage disequilib-
rium formed by three VEGF polymorphisms upstream 
of the coding sequence (promoter and 5′ UTR). Three 
haplotypes based on VEGF −2578 C/A, −1498 C/T 
and −634 G/C were defined on the basis of the popu-
lation frequencies of the three SNPs (VEGF Haplo1: 
A–C–G 46.6%; VEGF Haplo 2: C–T–C 34%; and VEGF 
Haplo 3: C–T–G 16.5%). None of these haplotypes were 
significantly associated with clinical outcome. Haplo-
type analysis of eNOS polymorphisms showed a strong 
linkage disequilibrium between eNOS VNTR4a/b and 
eNOS +894 G/T (correlation coefficient, r2  =  0.084; 
Lewontin’s D′  =  0.926) and eNOS VNTR 4a/b and 
eNOS −786 T/C (r2  =  0.217, D′  =  0.903). Moreover, 
a weak correlation was found between eNOS +894 
G/T and eNOS −786 T/C polymorphisms (r2 =  0.156, 
D′  =  0.456). Three haplotypes based on eNOS VNTR 
4a/b and eNOS +894 G/T were defined: eNOS Haplo 1 
(4b-G, 50.2%), eNOS Haplo 2 (4b-T, 34.1%) and eNOS 
Haplo 3 (4a-G, 15.3%).
In the CT  +  B arm, patients homozygous for eNOS 
Haplo 1 (eNOS Haplo 1/Haplo 1) and the group com-
posed of eNOS Haplo 1/Haplo 1 patients and individuals 
homozygous for Haplo 2 (eNOS Haplo 2/Haplo 2) showed 
a significantly improved outcome compared to the other 
patients. In particular, a longer median PFS was observed 
in eNOS Haplo1/Haplo1 patients compared to the others 
in the CT + B group [17.8 months (95% CI 8.1–22.3) vs 
9.6 (95% CI 8.3–10.9) (P = 0.004)]; this was not observed 
in the CT only arm (10.3, 95% CI 8.0–15.0, vs. 9.0, 95% CI 
7.8–9.6, P = 0.123) (Table 4; Fig. 2a, b). More significant 
results were observed in the CT + B group when eNOS 
Haplo1/Haplo1 and eNOS Haplo 2/Haplo 2 patients were 
combined, with a median PFS of 15.0  months (95% CI 
10.6–18.7) compared to 9.1 (95% CI 7.4–10.1) months 
for those with other genotypes (P =  0.001). Both eNOS 
haplotyes reached the P value threshold adjusted for FDR 
correction. No significant differences were observed in 
the control group (10.3, 95% CI 8.3–11.5, vs 9.0, 95% CI 
7.2–9.6, months, P = 0.542) (Table 4; Fig. 2c, d). 
Table 3 Association between VEGF and eNOS polymorphisms and overall survival (OS)
*Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).
Polymorphisms CT + B CT
Median OS (95% CI) HR (95% CI) P* Median OS (95% CI) HR (95% CI) P*
VEGF −2578
 AA 26.1 (9.0–34.5) 1.05 (0.61–1.81) 24.0 (14.4–36.7) 1.11 (0.67–1.85)
 CC/CA 21.4 (19.3–27.2) 1.00 0.854 20.8 (19.2–24.5) 1.00 0.671
VEGF −1498
 CC 26.1 (10.4–33.1) 1.12 (0.66–1.91) 26.6 (14.4–36.7) 0.95 (0.56–1.59)
 TT/CT 21.8 (19.3-27.2) 1.00 0.664 20.8 (18.8–24.3) 1.00 0.834
VEGF −1154
 AA 21.8 (2.3–30.4) 1.18 (0.53–2.63) 20.2 (11.1–29.2) 1.92 (0.96–3.85)
 GA/GG 21.4 (14.6–28.8) 1.00 0.686 25.2 (19.2–29.1) 1.00 0.066
VEGF −634
 GC 19.3 (13.1–22.0) 1.54 (0.98–2.44) 20.2 (16.8–24.3) 1.18 (0.76–1.82)
 GG/CC 29.1 (20.9–33.5) 1.00 0.064 24.3 (20.2–29.2) 1.00 0.456
VEGF +936
 TT 8.6 (7.9–13.9) 5.48 (1.60–18.8) 28.0 (–) 0.96 (0.11–7.98)
 CT/CC 22.7 (20.5–27.5) 1.00 0.007 21.3 (19.2–25.2) 1.00 0.967
eNOS +894
 GT 20.1 (12.0–23.2) 1.80 (1.12–2.89) 24.3 (17.9–28.6) 0.82 (0.53–1.25)
 GG/TT 26.1 (21.0–33.5) 1.00 0.014 21.3 (19.2–26.4) 1.00 0.356
eNOS VNTR
 4bb 24.8 (20.1–34.5) 0.54 (0.33–0.89) 23.6 (19.9–28.0) 0.76 (0.46–1.23)
 4ab/4aa 20.6 (13.7–24.7) 1.00 0.015 20.1 (15.0–23.3) 1.00 0.259
eNOS −786
 CC 27.2 (14.6–33.5) 0.97 (0.53–1.80) 20.4 (16.0–21.7) 1.40 (0.77–2.55)
 CT/TT 21.3 (16.4–27.4) 1.00 0.931 23.6 (19.9–28.0) 1.00 0.270
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Formal tests of interaction between haplotypes and 
treatment were not significant.
Moreover, a 71% ORR was observed in Haplo1/Haplo1 
and Haplo2/Haplo2 patients compared to 45.9% in 
patients with other genotypes (P = 0.013) (see Additional 
file 5). We also analyzed eNOS haplotypes in relation to 
OS. Patients with eNOS Haplo1/Haplo1 showed a longer 
median OS (31.6 months, 95% CI 19.3-not reached) than 
those with other genotypes (21.3, 95% CI 15.9–25.2) 
(P  =  0.016), the statistical significance was  more evi-
dent for eNOS Haplo1/Haplo1 and eNOS Haplo2/Haplo2 
patients (34.5, 95% CI 23.4–38.4, vs 20.5, 95% CI 14.4–
22.7, respectively, P = 0.002) (Table 4). This latter eNOS 
haplotype passed the FDR correction. No differences 
were observed within the control group in relation to 
these different genotypes (Table 4). The results obtained 
were independent of KRAS status.
Interestingly, with regard to the other genotypes, no 
differences in PFS or OS were observed between patients 
who were treated or not with B (median PFS 9.1 vs 
9.0 months and median OS 20.5 vs 20.8 months, respec-
tively). Conversely, the benefit of B was clearly visible in 
patients carrying the identified haplotype combination 
(Table 4).
Discussion
The present study analyzed VEGF and eNOS poly-
morphisms in relation to clinical outcome in patients 
with metastatic colorectal cancer receiving bevaci-
zumab-based chemotherapy. Although numerous stud-
ies have reported significant results regarding VEGF 
polymorphisms, others have failed to show such asso-
ciations, perhaps because of different study designs. A 
retrospective study by Loupakis and colleagues [11], 
hypothesized a role of the VEGF −1498 C/T polymor-
phism as a predictive biomarker of bevacizumab efficacy, 
showing that patients with a VEGF −1498 TT genotype 
had a worse prognosis. However, the same authors did 
not confirm this hypothesis in a subsequent prospec-
tive study [12] in which only another SNP, VEGFR2 
rs12505758, was found to be significantly correlated 
with PFS. In another retrospective study, VEGF −1498 
C/T and −2578 A/C were found to be correlated with 
outcome. In particular, the VEGF −2578 CC and −1498 
CC genotypes were associated with lower response and 
hypertension [10]. In other prospective studies, VEGF 
−1154 G/A [9] and VEGF −634 G/C [8] were signifi-
cantly correlated with patient outcome. However, neither 
study had a chemotherapy only (control) group, making 
it impossible to reach definitive conclusions.
One strength of our study was the fact that molecular 
analyses were performed on patients enrolled onto a ran-
domized, prospective phase III multicentre study (ITACa 
trial) in which two treatment arms were analyzed: 
chemotherapy plus bevacizumab vs chemotherapy only 
(highest level of evidence). Our results did not confirm 
the predictive value of VEGF −2578, −1498 and −1154 
polymorphisms, whereas VEGF −634 was found to be 
associated with OS. In particular, patients with a hete-
rozygous genotype showed a significantly lower ORR and 
a lower OS with a trend toward statistical significance. 
The poorer outcome observed with the heterozygous 
Table 4 Association between eNOS Haplotypes and PFS and OS
*Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).
eNOS haplotypes CT + B CT
n Median PFS (95% CI) HR (95% CI) P* n Median PFS (95% CI) HR (95% CI) P*
Haplo1/Haplo1 24 17.8 (8.1–22.3) 0.46 (0.27–0.78) 33 10.3 (8.0–15.0) 0.71 (0.46–1.10)
Other 90 9.6 (8.3–10.9) 1.00 0.004 86 9.0 (7.8–9.6) 1.00 0.123
Haplo2/Haplo2 15 13.1 (7.2–15.7) 0.82 (0.46–1.46) 16 9.9 (5.9–11.5) 1.44 (0.82–2.51)
Other 99 9.6 (8.3–11.3) 1.00 0.501 107 9.0 (8.3–10.2) 1.00 0.199
Haplo1/Haplo1 + Haplo2/Haplo2 39 15.0 (10.6–18.7) 0.48 (0.30–0.75) 49 10.3 (8.3–11.5) 0.88 (0.60–1.31)
Other 75 9.1 (7.4–10.1) 1.00 0.001 70 9.0 (7.2–9.6) 1.00 0.542
eNOS haplotypes CT + B CT
n Median OS (95% CI) HR (95% CI) P* n Median OS (95% CI) HR (95% CI) P*
Haplo1/Haplo1 24 31.6 (19.3–nr) 0.46 (0.24–0.86) 33 23.2 (16.8–39.7) 0.80 (0.49–1.31)
Other 90 21.3 (15.9–25.2) 1.00 0.016 86 20.8 (18.2–24.5) 1.00 0.379
Haplo2/Haplo2 15 34.5 (13.1–42.9) 0.70 (0.37–1.31) 16 21.3 (14.4–26.4) 1.35 (0.73–2.50)
Other 99 21.3 (16.4–24.7) 1.00 0.260 107 21.6 (19.2–27.1) 1.00 0.331
Haplo1/Haplo1 + Haplo2/Haplo2 39 34.5 (23.4–38.4) 0.42 (0.25–0.72) 49 21.7 (18.8–29.6) 0.95 (0.61–1.48)
Other 75 20.5 (14.4–22.7) 1.00 0.002 70 20.8 (18.2–27.1) 1.00 0.829
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genotype suggests that the presence of both alleles 
enhance their negative effect. Moreover, in our case 
series, the three patients with a VEGF +936 TT showed a 
shorter PFS and a substantially shorter OS. This finding, 
albeit based on a small number of patients, remained sta-
tistically significant after multiple testing corrections and 
might be worth validating in a larger case series.
The novelty of our work lies in its analysis of eNOS 
polymorphisms in relation to the clinical outcome of 
patients treated with bevacizumab. Our results show that 
eNOS +894 G/T and eNOS VNTR 4a/b were the most 
interesting polymorphisms. In particular, we identified a 
specific haplotype (eNOS Haplo1/Haplo1, characterised 
by eNOS +894GG and eNOS VNTR 4bb) that was sig-
nificantly associated with improved PFS and OS. Moreo-
ver, the combination of eNOS Haplo1/Haplo1 and eNOS 
Haplo 2/Haplo2 (characterised by eNOS +894TT and 
eNOS VNTR 4bb) accurately identified patients with a 
better ORR, PFS and OS. Interestingly, no significant 
associations were found in the group of patients treated 
with chemotherapy only, reinforcing the predictive value 
of the haplotypes in relation to bevacizumab efficacy.
eNOS is a constitutively expressed gene in endothelium 
involved in the production of nitric oxide (NO), which 
plays a central role in maintaining endothelial cell func-
tional integrity, regulating hemodynamics, and establish-
ing collateral circulation [19]. Adequate NO production, 
consequent to adequate eNOS expression and activity, 
is essential for preventing thrombotic and atherogenic 
processes [20]. It has been shown that VEGF inhibition 
induces a decrease in eNOS expression and thus in NO 
production [21], and that this phenomenon is linked to 
the induction of hypertension, one of the most common 
dose-limiting toxicities of VEGF inhibitors [22]. Previ-
ous studies have demonstrated an association between 
specific eNOS polymorphisms and hypertension [14, 23]. 
A positive correlation between the induction of hyper-
tension and the clinical benefit of bevacizumab has also 
been observed [13]. Although we did not observe a sta-
tistical significance between eNOS polymorphisms and 
Fig. 2 PFS in relation to Haplo1/Haplo1 (top panels) or Haplo1/Haplo1 plus Haplo2/Haplo2 (bottom panels) genotypes in patients treated with 
CT + B (a, c) or CT (b, d).
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hypertension (data not shown), we did find that eNOS 
genotypes associated with a better outcome were also 
associated with a trend towards higher grade hyperten-
sion. Intron 4 eNOS VNTR polymorphism plays a role 
in regulating eNOS expression by acting as an enhancer/
repressor and by coding for a 27-nt small RNA which 
appears to inhibit eNOS expression at the transcriptional 
level [24–27]. The higher the number of 27-nt repeats, the 
more 27nt sir-RNA is produced, inhibiting eNOS expres-
sion. However, the association between eNOS VNTR 
in intron 4 and eNOS expression is still a much debated 
issue [28–30]. Our results showed that patients homozy-
gous for the five repetitions (4bb), who presumably had 
a lower eNOS expression, showed a better response to 
bevacizumab. With respect to eNOS +894, it has been 
demonstrated that the +894 TT genotype is associated 
with lower eNOS activity [31–33]. In our study, the hap-
lotype most frequently associated with better PFS and 
OS was the one homozygous for eNOS VNTR 4bb and 
eNOS +894 TT. However, the association with the haplo-
type homozygous for eNOS VNTR 4bb and eNOS +894 
GG was also significantly associated with outcome. These 
results suggest that eNOS VNTR 4bb is the genotype 
most strongly correlated with response to bevacizumab. 
It also implies that, as eNOS is not the direct target of 
bevacizumab, other factors may be involved in the rela-
tion between eNOS activity and bevacizumab efficacy. 
In particular, it is possible that the variants are in linkage 
disequilibrium with other functional variants in the regu-
latory regions of the eNOS gene.
Our study was carried out on 63% (237/376) of the 
patients enrolled onto the ITACa study, a much higher 
percentage than those reported by other authors (26% for 
the AViTA trial and 17% for the AVOREN trial) [34]. This 
relatively low number of patients did not allow us to reach 
a sufficient statistical power to test the formal interaction 
between SNPs and clinical outcome or to consider our 
results definitively validated. Thus, although the work was 
based on patients from a randomized clinical trial with a 
control arm and SNP determinations were prospectively 
planned and centrally performed, our findings require 
further validation in independent and larger case series 
before they can be implemented into clinical practice.
Conclusions
In conclusion, we identified a haplotype combination 
of eNOS polymorphisms capable of identifying patients 
who may/will probably benefit from bevacizumab-based 
chemotherapy. No advantage was observed from the use 
of bevacizumab in patients not harboring the identified 
haplotype combination, whereas those carrying the spe-
cific genotype showed a significant improvement in ORR, 
PFS and OS. If confirmed in future studies, this haplotype 
combination could represent a valid criterion for select-
ing candidates for treatment with bevacizumab.
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